A population-based study on the impact of hospitalization for pneumonia in different age groups

BMC Infectious Diseases

Mario Saia¹  Francesca Russo¹  Chiara Bertoncello²  Patrizia Furlan²  Alessandra Buja²  Tatjana Baldovin²  Silvia Cocchio²  Vincenzo Baldo² 

[1] EuroHealth Net, Venice, Veneto Region Health Directorate, Dorsoduro 3493, 30123 Venezia, Italy;Department of Molecular Medicine, Public Health Section, University of Padua, Istituto di Igiene, Via Loredan 18, 35130 Padova, Italy

关键词: Vaccination;    Elderly;    Pneumonia;    Hospitalization;   

Others  :  1125643
DOI  :  10.1186/1471-2334-14-485

 received in 2014-04-18, accepted in 2014-09-03,  发布年份 2014

【 摘 要 】

Background

Pneumonia is an important cause of illness and death, particularly in elderly adults. This retrospective study was conducted to estimate the trend of hospitalization for pneumonia in the Veneto from the records of all hospitals in the region (serving a population of 4.81 million) during the years 2004 through 2012.

Methods

The cases of pneumonia identified in the hospital discharge records were all cases in which the first-listed diagnosis was pneumonia, or meningitis, septicemia or empyema associated with pneumonia. The annual total and age-specific hospitalization rates and trends were calculated and correlated with vaccine coverage. Total related costs were also calculated.

Results

There were 110,927 hospitalizations for pneumonia, meaning an annual rate of 256.3/100,000 population, with peaks in children and elderly people. The overall pneumonia-related hospitalization rate did not change significantly during the study period (AAPC: 1.3% [95% CI: −0.5, 3.1]). The rate dropped significantly among the 0- to 4-year-olds, however, from 617.3/100,000 in 2004 to 451.8/100,000 in 2012 (AAPC: −2.5% [95% CI: −4.5; −0.5]), while it increased slightly in adults aged 80+ (AAPC: 1.2% [95% CI: −0.9; 3.4]). The overall pneumonia-related mortality rate was 10.7%. The estimated cost per hospitalized patient was €3,090.

Conclusion

This study shows that hospitalization for pneumonia has a considerable impact on the health services, especially for children and the elderly. No decline in hospitalization rates was seen for the very elderly after the introduction of pneumococcal conjugate vaccination for children.

【 授权许可】

   
2014 Baldo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ: Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA 2005, 294:2712-2719.
• [2]Hebert PL, McBean AM, Kane RL: Explaining trends in hospitalizations for pneumonia and influenza in the elderly. Med Care Res Rev 2005, 62:560-582.
• [3]Thomsen RW, Riis A, Norgaard M, Jacobsen J, Christensen S, McDonald CJ, Sørensen HT: Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med 2006, 259:410-417.
• [4]Oosterheert JJ, Bonten MJ, Hak E, Lammers JW, Schneider MM, Hoepelman IM: The increase in pneumonia-related morbidity and mortality among adults in the Netherlands and possible explanations for it [in Dutch]. Ned Tijdschr Geneeskd 2004, 148:1765-1769.
• [5]Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG, U.S: Hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013, 369:155-163.
• [6]Welte T, Torres A, Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2010, 67:71-79.
• [7]WHO: Pneumococcal vaccines, WHO position paper – 2012. Wkly Epidemiol Rec 2012, 87:129-144.
• [8]Bhimraj A: Acute community-acquired bacterial meningitis in adults: an evidence-based review. Cleve Clin J Med 2012, 79:393-400.
• [9]Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000, 19:335-351.
• [10]Delibera della Giunta Regionale n. 203 del 03 febbraio 2009: Adozione della versione italiana 2007 dell’International Classification of Diseases 9th revision − Clinical Modification (ICD9CM) e della 24° versione del sistema di classificazione dei Diagnosis Related Groups (DRG). Bollettino Ufficiale Regione Veneto 2009, 17:67-69.
• [11]Garante per la protezione dei dati personali: Autorizzazione generale al trattamento dei dati personali effettuato per scopi di ricerca scientifica - 1° marzo 2012. Gazzetta Ufficiale della Repubblica Italiana 2012. Gazzetta Ufficiale della Repubblica Italiana 2012, 72:47-52.
• [12]Boehmer TK, Patnaik JL, Burnite SJ, Ghosh TS, Gershman K, Vogt RL: Use of hospital discharge data to evaluate notifiable disease reporting to Colorado’s electronic disease reporting system. Public Health Rep 2011, 126:100-106.
• [13]Servizio promozione e sviluppo Igiene e Sanità Pubblica: Indicazioni in Merito Alla Somministrazione del Vaccino Antipneumococcico Prevenar 13 in età Pediatrica. Venezia 2 luglio: Circolare della Regione Veneto; 2010.
• [14]Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, Marensi L, Giacchino R, Timitilli A, Carloni R, Azzari C, Icardi G: Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009, 27:3459-3462.
• [15]Martinelli D, Pedalino B, Cappelli MG, Caputi G, Sallustio A, Fortunato F, Tafuri S, Cozza V, Germinario C, Chironna M, Prato R: Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010–2013. Hum Vaccin Immunother 2014, 10:33-39.
• [16]Bartlett JG: Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011, 52:S296-S304.
• [17]Longini IM, Halloran ME, Nizam A: Model-based estimation of vaccine effects from community vaccine trials. Stat Med 2002, 21:481-495.
• [18]Fine P, Eames K, Heymann DL: “Herd immunity”: a rough guide. Clin Infect Dis 2011, 52:911-916.
• [19]Russo F, Pozza F, Napoletano G, Zanella F, Baldovin T, Lazzari R, Cocchio S, Baldo V: Experience of vaccination against invasive bacterial diseases in Veneto Region (north east Italy). J Prev Med Hyg 2012, 53:113-115.
• [20]Kim TH, Johnstone J, Loeb M: Vaccine herd effect. Scand J Infect Dis 2011, 43:683-689.
• [21]Ministry of Health: Italian Vaccine Coverage. http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=811&area=Malattie%20infettive&menu=vaccinazioni webcite. Accessed 9 Sep 2014
• [22]Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA, Rodriguez-Blanco T, Salsench E, Fuentes CM: Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010, 10:73. doi:10.1186/1471-2334-10-73 BioMed Central Full Text
• [23]Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG: Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 2007, 196:1346-1354.
• [24]Moberley S, Holden J, Tatham DP, Andrews RM: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:CD000422. doi: 10.1002/14651858.CD000422.pub3
• [25]Servizio promozione e sviluppo Igiene e Sanità Pubblica: Somministrazione Vaccino Antipneumococcico. Venezia 6 settembre: Circolare della Regione Veneto; 2013.
• [26]Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, Hoppe-Bauer J, Dunne WM, Kollef MH: Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia. J Hosp Med 2011, 6(7):405-410.
• [27]Venier AG, Gruson D, Lavigne T, Jarno P, L’Heriteau F, Coignard B, Savey A, Rogues AM: Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect 2011, 79(1):44-48.